Latest News

Progressive MS trials – design and interpretation


Part 2

Click here to take the survey

Part 1 of this article examined how the definitions of secondary-progressive and primary-progressive MS (SPMS, PPMS) have evolved and the contentious role that focal inflammatory activity has played (See Secondary-progressive MS: conceptual and practical challenges, NeuroSens, April 17, 2019). One shift has been to view the phenotypes of SPMS and PPMS as virtually indistinguishable with respect to their pathophysiology and clinical course, so both SPMS and PPMS trials will be considered here. Read More


ECTRIMS 2019 Survey


NeuroSens will be onsite in Stockholm to attend this year’s meeting of the European Committee on Treatment and Research in MS (ECTRIMS). Complete the survey below to tell us what topics are of greatest interest to you. Read More